FDA’s Modernization Plans Gain Momentum in Expediting Healthcare Innovation

The U.S. Food and Drug Administration’s (FDA) multifaceted responsibilities require continuous monitoring of trends in science and technology for the advancement of public health. In early 2020, the agency saw investigational new drug (IND) applications skyrocket to 3,806 — a significant increase compared to the previous year when they received only 166 applications during the same months.1